• CalendarMay 22, 2018 – "Sovereign Immunity and Patents at the PTAB and District Courts" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    May 22, 2018 – "Last Party Standing: Who Has Standing to Appeal Administrative Decisions to the Federal Circuit?" (Federal Circuit Bar Association) – 3:00 pm to 4:30 pm (EST)

    May 22, 2018 – "Nuances in Amending Patent Claims before the PTAB and Avoiding Tribal Immunity at the PTAB" (Intellectual Property Law Association of Chicago Litigation Committee) – 5:00 to 7:30 pm (CT), Chicago, IL

    May 24, 2018 – "Divided Infringement after Travel Sentry v. Tropp: Direct Infringement Liability for Third-Party Conduct" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 31, 2018 – "Oil States and SAS: Implications of the Supreme Court's Decisions for Patent Practice" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 31, 2018 – "The Defend Trade Secrets Act Turns Two: New Perspectives and Analysis on the Current State of the Law" (LexisNexis) – 1:30 to 2:00 pm (ET)

    June 4-7, 2018 – BIO International Convention (Biotechnology Innovation Organization) – Boston, MA

    June 5, 2018 – "Functional Claiming for Software Patents: Leveraging Recent Court Treatment — Surviving 112(f) and Disclosing Functional Basis for Software to Meet Heightened Standard of Review" (Strafford) – 1:00 to 2:30 pm (EDT)

    June 13-15, 2018 – Patent Fundamentals Bootcamp 2018: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – New York, NY

    June 25-27, 2018 – Summit on Biosimilars (American Conference Institute) – New York, NY

    July 18-20, 2018 – Patent Fundamentals Bootcamp 2018: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – San Francisco, CA

    September 21, 2018 – "USPTO Post-Grant Patent Trials 2018: Change & Recalibration" (Practising Law Institute) – New York & Groupcasts in Philadelphia, Indianapolis, New Brunswick, NJ, Pittsburgh, and Mechanicsburg, PA

  • LexisNexisLexisNexis will be offering a webinar on "The Defend Trade Secrets Act Turns Two: New Perspectives and Analysis on the Current State of the Law" on May 31, 2018 from 1:30 to 2:00 pm (ET).  Jyotin Hamid and Tricia Sherno of Debevoise & Plimpton LLP will discuss the influence of the Defend Trade Secrets Act (DTSA) on intellectual property and employment practice and the current state of the law including:

    • How trade secret litigation has changed with the DTSA
    • Establishing a trade secret and confidentiality under the DTSA
    • The availability of the "inevitable disclosure" theory under the DTSA
    • Remedies and damages available under the DTSA
    • Notice provisions in employment agreements and employee confidentiality agreements
    • Recent trade secret cases and emerging issues

    Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Functional Claiming for Software Patents: Leveraging Recent Court Treatment — Surviving 112(f) and Disclosing Functional Basis for Software to Meet Heightened Standard of Review" on June 5, 2018 from 1:00 to 2:30 pm (EDT).  Cory C. Bell and Doris Johnson Hines of Finnegan Henderson Farabow Garrett & Dunner will guide IP counsel on functional claiming in software patents and USPTO prosecution, examine recent court treatment, and explain how to navigate the issue of functionality given the uncertainties in the prosecution and litigation contexts.  The webinar will review the following issues:

    • What has the impact of the Williamson decision been on functional claim interpretation for software patents?
    • What are the benefits and limitations of using functional claims for software patents?
    • What are the lessons from recent decisions regarding functionality in software patents?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • By Donald Zuhn

    Anacor PharmaceuticalsOn Monday, the Federal Circuit affirmed the determination by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board in an inter partes review that claim 6 of U.S. Patent No. 7,582,621 is unpatentable for obviousness.  On appeal, Anacor Pharmaceuticals, Inc., the assignee of the '621 patent, challenged the Board's reasoning in finding claim 6 to be invalid.

    The '621 patent is directed to the use of 1,3-dihydro-5-fluoro-1-hydroxy-2, 1-benzoxaborole, also known as tavaborole, as a topical treatment for fungal infections that develop under fingernails and toenails.  In particular, the '621 patent discloses that tavaborole can be used to treat a fungal infection known as onychomycosis, most frequently caused by dermatophytes (in approximately 90% of cases), which is a group of fungi that includes the genus Trichophyton and the species Trichophyton rubrum.  However, onychomycosis can also be caused by another fungus, a yeast known as Candida albicans (in 5% of cases).  The single claim at issue on appeal was claim 6, which depends from claim 4, which depends in turn from claim 1.  Claims 1, 4, and 6 recite:

    1.  A method of treating an infection in an animal, said method comprising administering to the animal a therapeutically effective amount of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof, sufficient to treat said infection.

    4.  The method of claim 1, wherein said infection is onychomycosis.

    6.  The method of claim 4, wherein said onychomycosis is tinea unguium.

    Tinea unguium is onychomycosis caused by a dermatophyte.

    In 2015, the Coalition for Affordable Drugs X LLC filed a petition requesting inter partes review of all twelve claims of the '621 patent, and the Board ultimately determined that the claims would have been obvious in light of the combination of International Application No. PCT/GB95/01206 ("Austin") and U.S. Application No. 10/077,521 ("Brehove").  Austin discloses: (a) the use of oxaboroles — boron heterocycles that include a five-member ring containing three carbon atoms, one oxygen atom, and one boron atom — as fungicides; and (b) that tavaborole, an oxaborole, has antifungal activity and is a highly effective agent for inhibiting a variety of fungi, including C. albicans.  Brehove discloses: (a) the use of boron heterocycles in a topical composition to treat onychomycosis; (b) that two dioxaborinanes — boron heterocycles that include a six-member ring containing three carbon atoms, two oxygen atoms, and one boron atom — were shown in in vitro testing to have powerful potency against C. albicans; and (c) in in vivo tests on five individuals with onychomycosis, the fungal infection was successfully treated by topical application of the two dioxaborinanes.

    In its final written decision, the Board determined that Austin discloses that tavaborole is a known fungicide with particular potency against C. albicans, and that molecular weight was the most important factor in predicting whether a molecule would penetrate the nail plate.  In particular, the Board noted that of the seven tested compounds listed in Table 9 of Austin, tavaborole was the most effective against various fungi, including C. albicans, and of the nine compounds listed in Table 8 of Austin, tavaborole had the lowest molecular weight.  The Board also determined that Brehove disclosed the treatment of onychomycosis with boron heterocycles and that Brehove's compounds were effective against C. albicans.  The Board concluded that one of ordinary skill in the art would have used Austin's tavaborole in Brehove's topical treatment of onychomycosis with a reasonable expectation of success.  While acknowledging that "neither Austin nor Brehove expressly teaches whether the disclosed compounds exhibit any activity against dermatophytes" (with respect to claim 6), the Board determined that "the weight of the evidence favors Petitioner's argument" because the skilled artisan would have expected that tavaborole, which shares functional activity with the compounds of Brehove against C. albicans would also share functional activity against other fungi responsible for onychomycosis, namely dermatophytes.

    On appeal, Anacor argued that: (1) the Board violated due process and the procedural requirements of the Administrative Procedure Act by failing to provide Anacor with adequate notice of, and an opportunity to respond to, the grounds of rejection ultimately adopted by the Board; (2) the Board improperly shifted the burden of proof by requiring the patent owner to disprove obviousness; and (3) the Board incorrectly concluded that the compounds of Austin are structurally similar to the compounds of Brehove.  In an opinion authored by Judge Bryson, and joined by Judge Reyna and Judge Stoll, the Federal Circuit rejected Anacor's challenges to the Board's reasoning and upheld the Board's conclusion that claim 6 of the '621 patent is invalid for obviousness.

    With respect to Anacor's first argument, based on its assertion that the Petitioner shifted to a new theory of obviousness and that the Board adopted that new theory without giving Anacor proper notice or an opportunity to respond to it, the Federal Circuit rejected such assertion, finding instead that "the Board's final written decision was based on the same combination of references—Austin and Brehove—and the same series of inferences that the petition proposed."  In response to Anacor's related assertion that the Petitioner had impermissibly relied on new evidence, not included in the petition, to satisfy its burden of showing a prima facie case of obviousness, the Federal Circuit noted that:

    There is . . . no blanket prohibition against the introduction of new evidence during an inter partes review proceeding.  In fact, "the introduction of new evidence in the course of the trial is to be expected in inter partes review trial proceedings and, as long as the opposing party is given notice of the evidence and an opportunity to respond to it, the introduction of such evidence is perfectly permissible under the APA" [citing Genzyme Therapeutic Prod. Ltd. P'ship v. Biomarin Pharm. Inc., 825 F.3d 1360, 1366 (Fed. Cir. 2016)].

    Moreover, the Court also noted that of the three references (in addition to Austin and Brehove) cited by the Board in its final written decision, Anacor discussed two of the references in its patent owner's response and related submissions, one of Anacor's experts admitted to familiarity with the third reference (which related to two earlier installments by the same author that were cited in that expert's declaration), another Anacor expert was questioned about the third reference during his deposition, and Anacor discussed the third reference during the hearing before the Board.  The panel therefore concluded that "Anacor was not denied its procedural rights with respect to the theory of obviousness adopted by the Board or any evidence relied on by the Board."

    With respect to Anacor's second argument that the Board improperly shifted the burden of proof by requiring the patent owner to disprove obviousness, Anacor contended that the record provided no basis to conclude that tavaborole's activity against dermatophytes would be expected.  The Federal Circuit, however, noted that:

    In light of the fact that approximately 90 percent of all onychomycosis cases are attributable to dermatophytes, and in the absence of any evidence that patients with dermatophyte-based onychomycosis were excluded from the in vivo testing, it is highly likely that at least some of the five cases discussed by Brehove involved dermatophyte infections.

    The panel therefore concluded that "substantial evidence supports the Board's findings that a person of ordinary skill in the art would have been motivated to combine the pertinent teachings of Austin and Brehove and would have had a reasonable expectation of success in doing so."

    Finally, with respect to Anacor's third argument that the Board incorrectly concluded that the compounds of Austin are structurally similar to the compounds of Brehove, the Federal Circuit determined that "although there is only limited structural similarity between the compounds disclosed in Austin and Brehove, . . . in light of the combination of the structural and functional similarities between the compounds, substantial evidence supports the Board's findings."

    Anacor Pharmaceuticals, Inc. v. Iancu (Fed. Cir. 2018)
    Panel: Circuit Judges Reyna, Bryson, and Stoll
    Opinion by Circuit Judge Bryson

  • By Kevin E. Noonan

    Federal Circuit SealThe proper application of the patent venue statute, 28 U.S.C. § 1400(b) in the wake of the Supreme Court's decision in TC Heartland LLC v. Kraft Foods Group Brands LLC (2017), under recent Federal Circuit precedent (see In re Cray, Inc.) continues to be explicated in the district courts.  The most recent episode in this continuing saga is a mandamus order handed down by the Federal Circuit today in In re BigCommerce, Inc.  Specifically, the Court held:

    [W]e hold that for purposes of determining venue under § 1400(b) in a state having multiple judicial districts, a corporate defendant shall be considered to "reside" only in the single judicial district within that state where it maintains a principal place of business, or, failing that, the judicial district in which its registered office is located.

    This is a considerable restriction on the already limited venue options open to plaintiffs, which limited proper venue to states where the defendant resides (its state of incorporation) or "where the defendant has committed acts of infringement and has a regular and established place of business."

    The case arose in the Eastern District of Texas, Marshall Division, where respondents Diem LLC and Express Mobile Inc. individually filed patent infringement suits against BigCommerce.  BigCommerce filed a motion to dismiss for improper venue in the Diem case, and a motion to transfer in the Express Mobile case; each of these motions was denied by the District Court.  As noted in the Federal Circuit's Order, "[i]t is undisputed that BigCommerce has no place of business in the Eastern District of Texas" (rather, its registered office and headquarters is in Austin, which is in the Western District of Texas).  Nevertheless, the Diem court ruled that "a domestic corporation resides in the state of its incorporation and if that state contains more than one judicial district, the corporate defendant resides in each such judicial district for venue purposes" and the Express Mobile court found nothing in plaintiff's argument that distinguished this reasoning.

    The Federal Circuit issued a mandamus order overturning these decisions, despite the acknowledged "heavy burden" placed on a petitioner for obtaining one, by Judge Linn joined by Judges Reyna and Hughes.  The Court found "exceptional circumstances" here, specifically that "basic" and "undecided" questions were involved as required by the Supreme Court in Schlagenhauf v. Holder, 379 U.S. 104, 110 (1964).  The order states there is "no doubt" that venue is proper for a domestic corporation only in its state of incorporation, but that there is inconsistent precedent regarding whether venue is limited in states having more than one judicial district.  The Court also recognized that this issue had not been addressed in its Cray decision and thus "will inevitably be repeated," further justifying issuing the writ in this case.  In this regard the order also notes that the magistrate's decision in the Diem case, that BigCommerce had waived its venue objections, was "clearly incorrect as a matter of law" under the Court's In re Micron Tech., Inc., 875 F.3d 1091 (Fed. Cir. 2017) precedent.

    The Court's substantive decision, that "a domestic corporation incorporated in a state having multiple judicial districts [does not] 'reside[]' for purposes of the patent-specific venue statute, § 1400(b), in each and every judicial district in that state" was based, according to the order, on "the statute's language, history, purpose, and precedent."  The plain language of the statute recites "judicial district" in the singular which has been held in other contexts as meaning a single place according to the panel, citing Hertz Corp. v. Friend, 559 U.S. 77, 93 (2010); NLRB v. Canning, 134 S. Ct. 2550, 2561 (2014); and Rumsfeld v. Padilla, 542 U.S. 426, 434 (2004).  The order finds that the history of § 1400(b) is consistent with this construction, citing language in the 1897 predecessor to the current statute and that Congress did not intend to change the scope of the statute in its revisions in 1948, citing the Supreme Court's decision in Fourco Glass Co. v. Transmirra Products Corp., 353 U.S. 222 (1957).  The panel also considered this reading consistent with the broader venue provisions of 28 U.S.C. § 1391(c) (1952), and that Congress had evinced an intent that venue in patent cases should be more limited than in general civil litigation contexts, citing Brunette Mach. Works, Ltd. v. Kockum Indus., Inc., 406 U.S. 706, 713 (1972) for this proposition.

    The panel also found that the term "resides" was "a term of art that had a settled meaning in the law" consistent with limiting venue to the judicial district where a patent infringement defendant resides.  The order cites Federal Practice treatise as well as Supreme Court precedent, including Galveston, H. & S.A. Ry. Co. v. Gonzales, 151 U.S. 496, 504 (1894), and Stonite Products Co. v. Melvin Lloyd Co., 315 U.S. 561 (1942), as well as Fourco in support of the "well-established" status of the meaning of "resides," with Stonite being particularly relevant; there, two corporate defendants were "both incorporated in the state of Pennsylvania but maintained principal places of business in different judicial districts (like here, there being Eastern and Western judicial districts in Pennsylvania).

    The Court's Order also reviewed and rejected three arguments from respondents.  The first was that the use of "resides" in earlier Supreme Court cases (including Stonite) is in tension with later Supreme Court cases (including Fourco).  The Federal Circuit rejected this argument almost out of hand, saying that the Court did not address the issue in Fourco at the judicial district level of granularity, "and set a necessary but not necessarily sufficient condition for corporate residence for venue under § 1400(b)" (emphasis in order).  The second argument, that modern business circumstances counseled a "more flexib[le]" approach was "a non-starter," the panel stating that "'[t]he requirement of venue is specific and unambiguous; it is not one of those vague principles which, in the interest of some overriding policy, is to be given a 'liberal' construction," quoting Olberding v. Ill. Cent. R.R. Co., 346 U.S. 338, 340 (1953), as cited in Schnell v. Peter Eckrich & Sons, Inc., 365 U.S. 260, 264 (1961), and saying that "[s]uch policy-based arguments are best directed to Congress."  Finally, the order addresses the question generally regarding how venue should be properly decided in multi-judicial district states.  First, the proper district for venue would be the district in which the defendant has a principal place of business (if there is such a place in the state), citing Galveston, H. & S.A. Ry. Co. v. Gonzales, 151 U.S. 496, 504 (1894).  And the Court noted that a "principal place of business" is not the same as "a regular and established place of business" as required by other aspects of the statute, the order citing Hertz Corp. v. Friend, 559 U.S. 77, 93 (2010).  In the absence of a "principal place of business" in a state in which a defendant is incorporated, the "default' should be the judicial district in which the corporation has its registered office or agent, calling this a "universally recognized foundational requirement of corporate formation."

    Thus, the contraction of proper venue for suing patent infringement defendants continues, with this current decision limiting venue to those districts having the closest ties with the accused infringer.  It would not be incorrect to count this decision as another judicial encroachment on the ability of patentees to assert their patents.

    In re BigCommerce, Inc. (Fed. Cir. 2018)
    Panel: Circuit Judges Reyna, Linn, and Hughes
    Order by Circuit Judge Linn

  • By Andrew Williams

    Federal Circuit SealSince the Supreme Court's decision in TC Heartland LLC v. Kraft Foods Group Brands LLC last year, there have been hundreds of district court cases that have determined (or reconsidered) whether venue was proper.  Correspondingly, because there have been "basic" and "undecided" issues necessary to address the effect of the TC Heartland case, the Federal Circuit has granted a few petitions for Writ of Mandamus because "[t]hese issues are likely to be repeated and present sufficiently exceptional circumstances . . . ."  For example, the Court explained in In re Cray what constitutes a "regular and established place of business," and in In re Micron whether defendants have or have not waived their venue defense.  This week, the Court granted two more petitions to address additional implications of the Supreme Court's case.  In one of these cases, In re ZTE (USA) Inc., the Court addressed the question about which party has the burden in establishing whether venue is proper (or improper) in a particular case.  In this case, the Federal Circuit vacated an Eastern District of Texas order denying a motion to dismiss for improper venue and instructed the District Court to place the burden of persuasion with regard to the propriety of venue on the Plaintiff.

    The underlying case was American GNC Corporation v. ZTE Corporation, No. 4:17-cv-00620-ALM-KPJ, and was filed in the Eastern District of Texas.  The case was initially filed in the Marshall Division, but was transferred to the Sherman Division before the motion on venue was denied.  On October 4, 2017, Magistrate Judge Johnson recommended denying a motion to dismiss for improper venue.  In so doing, she noted that "[a]lthough courts are not uniform in their views as to which party bears the burden of proof with respect to venue, the majority of Fifth Circuit cases hold that the burden is on the objecting defendant to establish that venue is improper."  She also found that ZTE USA had a dedicated call center in Plano, Texas.  And even though ZTE USA alleged that the call center was established in partnership with a third party and did not qualify as a regular and established place of business, Magistrate Judge Johnson found that ZTE USA had failed to meet its burden to show that the call center was not.  U.S. District Judge Mazzant adopted the report and recommendations over ZTE USA's objections, and denied the motion to dismiss on November 7, 2017.

    After determining that this issue was "amenable to resolution via mandamus," the Federal Circuit analyzed whether it involved a question "'related' to 'substantive matters unique to the Federal Circuit . . . .'"  The Court had already determined in In re Cray that whether venue was proper under § 1400(b) was an issue unique to patent law.  Moreover, the Court explained that which party bears the burden of persuasion for a legal rule is often treated as a substantive question, citing Supreme Court precedent from 1942 to the recent Medtronic, Inc. v. Mirowksi Family Ventures, LLC case from 2014.  In addition, the Court pointed out that all appeals from cases that involve § 1400(b)-venue questions will come to it, so uniformity at the lower court level will "obviate any uncertainty . . . ."  As a result, the Federal Circuit concluded "that the patent-specific nature of §1400(b) also implicates the burden for satisfying that statute, and should be analyzed under this court's law."

    The Federal Circuit next analyzed the question of which party bears the burden.  Interestingly, the Court could not find a case in which the issue had been addressed in its 37-year history.  However, prior to the formation of the Federal Circuit, the regional circuits handled challenges to venue in patent cases by placing the burden on Plaintiffs.  Even though this precedent might not have been binding on the Court, it was persuasive.  Moreover, the Court noted that the restrictive nature of the patent-specific venue statute (as opposed to the more general venue statute of § 1391) supports placing the burden on the Plaintiff.  Correspondingly, the Court held that "as a matter of Federal Circuit law, that upon motion by the Defendant challenging venue in a patent case, the Plaintiff bears the burden of establishing proper venue."

    Finally, with regard to the merits of the venue determination, the Federal Circuit held that the District Court did not make a proper showing because it essentially rested on the fact that ZTE USA failed to meet its burden.  Even though In re Cray dealt with the alleged "place of business" being an employee's house and not a call center, it did establish what is required to show whether the second prong of the venue statute is established, namely "(1) there must be a physical place in the district; (2) it must be a regular and established place of business; and (3) it must be the place of the defendant."  Therefore, the lower court was required to "give reasoned consideration to all relevant factors or attributes of the relationship in determining whether those attributes warrant iQor's call center being deemed a regular and established place of business of ZTE USA."  Because the District Court did not do this, the Federal Circuit vacated and remanded.

    So what will be the impact of this decision?  For district courts that have already been placing the burden on Plaintiffs, there will not be much effect.  However, the districts where the question of proper venue has probably been addressed the most, namely Delaware and the Texas districts (located in the Third and Fifth Circuits respectively), the courts have been placing the burden on the defendants that move to dismiss or transfer.  Therefore, there might be a shift in the outcome in such cases.  For example, for ANDA cases, the District of Delaware and the Northern District of Texas had created two different tests for whether venue is proper in the Hatch-Waxman context.  Chief Judge Stark from the Delaware court in Bristol-Myers Squibb Company v. Mylan concluded that "the 'acts of infringement' an ANDA filer 'has committed' includes all of the acts that would constitute ordinary patent infringement if, upon FDA approval, the generic drug product is launched into the market."  On the other hand, Chief Judge Lynn of the Northern District of Texas in Galderma Laboratories, L.P. v. Teva Pharmaceuticals USA, Inc. focused on the act of infringement being the submission of the ANDA.  It is unlikely that In re ZTE (USA) will impact this split.  Chief Judge Stark has been allowing limited venue discovery in such cases, and this is unlikely to change based on the recent decision.  And in Galderma, because neither party alleged that Teva USA had prepared or submitted its ANDA from Texas, there was no act of infringement found (and thus the issue of whether there was a "regular and established place of business" was moot).  Nevertheless, moving forward, defendants will have little to lose in bringing a motion to dismiss or transfer because of improper venue in all but the clearest cases, so plaintiffs will need to be prepared for such challenges (ideally before the complaint is filed).

    In re ZTE (USA) Inc. (Fed. Cir. 2018)
    Panel: Circuit Judges Reyna, Linn, and Hughes
    Order by Circuit Judge Linn

  • By Michael Borella

    USPTO SealThe Patent Trial and Appeal Broad (PTAB) of the U.S. Patent and Trademark Office has often been criticized for being particularly harsh when reviewing appeals of claims rejected by an examiner of grounds of patent-ineligibly under 35 U.S.C. § 101.  According to some sources, examiners are affirmed about 80-86% of the time in these matters.[1]  Therefore, when the PTAB reverses an examiner's § 101 rejection, it is worthwhile to note how and why.

    U.S. Patent Application No. 13/961,567 was filed in August of 2013, and finally rejected three years later.  The Applicant appealed to the PTAB soon after, and a decision was handed down earlier this month.

    According to the PTAB:

    The claimed subject matter relates to mapping and characterizing sea ice from synthetic aperture radar (SAR) measurements.  The ability to characterize sea ice is becoming increasingly important as the makeup of ice that covers various surfaces of the globe is changing and the characteristics of the ice have changed dramatically in recent years.  Both environmental concerns and natural resource concerns have a great deal of interest in measuring and characterizing regions of the earth that have ice coverage.  The structure, thickness, and location of sea ice are of particular interest.

    The claimed subject matter uses dual frequency (X- and P-band) data acquired from synthetic aperture radar (SAR) systems to determine sea ice depth and the presence of leads in the ice floe.  The P-band SAR penetrates ice to 5 to 10 meters or more, while the X-band SAR images the surface of the ice.  The claimed subject matter also uses co-polarized (e.g., HH and VV) P-band data obtained from a SAR system to map ice structures and weak points in the ice floe.

    As a representative example, claim 1 recites:

    A method of generating and using mapping layers, comprising:
        acquiring, via a synthetic aperture radar (SAR) system, full polarity SAR data over an area containing sea ice, wherein the acquired full polarity SAR data includes X-band data and P-band data;
        storing the acquired full polarity SAR data in a SAR database;
        generating layers via a processor of the SAR system by performing interferometric processing operations on the acquired full polarity SAR data that includes the X-band data and the P-band data;
        registering, by the processor, the generated layers one to another geographically; and
        determining, by the processor, a depth of the sea ice by combining the generated layers.

    The Examiner rejected claims 1-7, 15-21, 23, 24, and 28-33 under § 101 as allegedly being directed to an abstract idea and not including significantly more than that idea.

    The Supreme Court's Alice Corp. v. CLS Bank Int'l case set forth a test to determine whether claims are directed to patent-eligible subject matter under 35 U.S.C. § 101.  One must first decide whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further decide whether any element or combination of elements in the claim is sufficient to ensure that the claim amounts to "significantly more" than the judicial exclusion.  But generic computer implementation of an otherwise abstract process does not qualify as significantly more.  On the other hand, a claimed improvement to a computer or technological process is typically patent-eligible.

    The PTAB began its analysis by describing the aforementioned Alice decision, as well as the Federal Circuit's follow-on decision in McRO, Inc. v. Bandai Namco Games America Inc.  Regarding the latter case, the PTAB noted that the Court held claims directed to a rules-based lip-synchronization process to be patent eligible because, among other reasons, "the claims do not simply use a computer as a tool to automate conventional activity," and that there was "no evidence that the process previously used by animators is the same as the process required by the claims."

    Concerning the present invention, the PTAB put a heavy emphasis on the teachings of the specification.  In particular, the specification "describes that prior art attempts at using SAR and IFSAR to measure and characterize sea ice have used satellite-based X-band systems or airborne systems to map the top of ice through a few decimeters of dry snow and characterize only new from first-year and multiyear ice."  But these systems did not measure ice thickness — instead low-flying radar or drilling techniques were used for such a purpose, resulting in thickness data only on small sections of ice.

    Applicant's SAR system, however, was different because "the P-band SAR penetrates the surface features and the ice itself to reveal details of surface and internal cracking of an ice floe not evident in X-band data."  Notably, the specification describes "the specific steps the processor employs to determine the thickness of the ice based on the X-band and P-band SAR data."  This includes "creating elevation models for the top of the ice based on the X-band digital elevation map, creating elevation models for the penetration depth based on the P-band HH digital elevation map, and subtracting these models to provide a direct measure of ice thickness."

    As a result, the PTAB found that the claimed improvement involves "the processor of a SAR system to determine ice thickness, leads in the ice, and ice cracks, each of which requires data taken from below the ice surface, that previously could only be produced over very small areas using low-flying profiling radar systems, sled-based ground penetrating radar, or core samples drilled from the ice."  Further "these characterizations of the sea ice are realized by improving the prior art using specific rules to combine and process dual-frequency SAR data and using specific rules to process particular types of P-band SAR data."

    While the Examiner contended that the claimed invention that did not differ from past manual techniques, the PTAB disagreed.  Specifically, the PTAB wrote that "[t]he record before us does not contain sufficient evidence to show that the claimed process is the same as any prior art process used to determine the claimed sea ice characteristics."  Moreover, there is nothing in the background of the specification that discloses using P-band SAR data for characterizing sea ice, and the Examiner had not pointed to any such disclosure in the prior art.

    The Examiner also contended that the claims are "merely a series of mathematical or logical operations that determines the depth of sea ice after merely generically gathering data used in the operation."  The PTAB disagreed, noting that the claims also recite "processing the acquired data to build layers of a map, and registering the layers together to create a depth map prior to calculating the ice thickness."  Thus, "the claim limitations amount to specific formatting of the data according to rules to identify leads and cracks in the ice," and "the claim limitations recite a combined order of specific rules that renders information into a specific format that is then used and applied to characterize the sea ice."

    Concluding, the PTAB asserted that "[t]he Examiner erred in oversimplifying the claims and characterizing them as directed to generic computer operations, mathematical algorithms, and mere automation of prior manual activity."  Therefore, the PTAB reversed the examiner's § 101 rejections.

    At first blush, claim 1 of the '567 application looks doomed under § 101.  This is because the Electric Power Group, LLC v. Alstom S.A. Federal Circuit case has been applied broadly by the Office to reject claims that are allegedly directed to no more than gathering data, processing the data, and providing a result.  Arguably, that is all that is going on in claim 1.  That case, however, was not even mentioned in this decision.  Perhaps this is because it was decided in August 2016, right before the '567 application was appealed.  Still it is somewhat surprising that the PTAB did not rely on, or even mention, Electric Power Group.

    Instead, the PTAB's emphasis on McRO and a detailed analysis of the teaching of the Applicant's specification won the day.  This might imply that even if a claim recites no more than gathering data, processing the data, and providing a result, when the claim also involves a technical advance, that is enough to overcome a § 101 challenge.  While it would be nice to have the PTAB (or even better, the Federal Circuit) explain where Electric Power Group ends and McRO begins, the outcome herein is a potentially persuasive holding that can be (and probably should be) cited when § 101 prosecution gets difficult.

    Ex Parte Reis (PTAB 2018)
    Panel: Administrative Patent Judges Linda E. Horner, Brett C. Martin, and Paul J. Korniczky
    Decision on Appeal by Administrative Patent Judge Horner

    [1] http://www.bilskiblog.com/blog/2017/09/surviving-alice-with-an-appeal.html; https://www.lexology.com/library/detail.aspx?g=b5dcb8ae-3478-4e4b-b344-38258b910431.

  • By Josh Rich

    Goldman SachsAs the saying goes, hard cases make bad law.  And it certainly looked improper when Sergey Aleynikov downloaded high-frequency trading ("HFT") source code as he was leaving his job as a Goldman Sachs programmer, at least to the juries who convicted him of Federal and New York state crimes.  But while the U.S. Court of Appeals for the Second Circuit overturned his conviction because the law did not fit the offense, the New York Court of Appeals (the highest court in the state) recently upheld his conviction on "Unlawful Use of Secret Scientific Material."  To reach that conclusion, however, the Court of Appeals had to construe two statutory provisions in ways that may have unintended — and unwanted — consequences for New York's criminal laws.

    To recap, Mr. Aleynikov left Goldman Sachs on June 5, 2009 to take a job with another trading firm where he would be writing HFT software.[1]  Before he left, first on June 1 then again on June 5 (his last day as an employee), he downloaded portions of the Goldman Sachs HFT software source code and uploaded them to a server in Germany.  He later downloaded the source code to his personal computer and allegedly used it to structure HFT code modules for his new employer.

    After discovering Mr. Aleynikov's actions, Goldman Sachs notified the FBI, who questioned Mr. Aleynikov about Goldman Sachs's allegations.  Mr. Aleynikov cooperated with the interrogation, admitting that he had downloaded the source code, but explaining that he had innocent motives.  The FBI and the U.S. Attorney did not see his actions as innocent; he was prosecuted in the Southern District of New York for violations of the Economic Espionage Act and National Stolen Property Act and found guilty under both laws.[2]  Upon appeal, however, the Second Circuit reversed his conviction on both counts.  Importantly, in doing so, it found that source code was "intangible property" and therefore not a "good" under the National Stolen Property Act.[3]

    Although the Second Circuit overturned Mr. Aleynikov's conviction, the FBI turned Mr. Aleynikov's computer, passport, and other materials over to the Manhattan District Attorney's Office rather than returning them to him.  The Manhattan D.A. then charged Mr. Aleynikov with two counts of Unlawful Use of Secret Scientific Material (each count tied to one of the two downloading sessions) and one count of Unlawful Duplication of Computer Related Material.  At trial, the jury convicted Mr. Aleynikov on the count of unlawful use related to his June 5 downloads, hung on the count of unlawful use related to his June 1 downloads, and acquitted him of unlawful duplication.  But the trial court (known in New York as the Supreme Court) overturned the jury conviction, reasoning (among other things) that Mr. Aleynikov had not made a "tangible reproduction or representation" of the Goldman HFT source code and that the prosecution had not shown that he had intended to "appropriate" the use of the code, both of which were statutory requirements for the unlawful use offense.[4]

    The appellate court (the Appellate Division of the Supreme Court) reversed the trial court order, reinstating the jury conviction on the unlawful use count.[5]  Whether the source code itself was tangible or intangible property was irrelevant to the appellate court.  Instead, it found that Mr. Aleynikov made a "tangible reproduction or representation" when he uploaded the source code to the German server because "when he copied it onto the server's 'physical' hard drive[,] it took up 'physical space' and was 'physically present."  With regard to the term "appropriate," defined in the New York Penal Law generally for all larceny offenses, the appellate court considered the portion of the definition that indicated that "[t]o 'appropriate' property of another to oneself or a third person means (a) to exercise control over it, or to aid a third person to exercise control over it, permanently . . . ."[6]  The appellate court focused on Mr. Aleynikov's intent with regard to the copy he had made of the secret scientific material, finding that there was no evidence that he had intended to return the copy, and therefore had appropriated it.

    Against this backdrop, the New York Court of Appeals accepted review to consider whether Mr. Aleynikov had made a "tangible reproduction or representation of [Goldman's HFT source code] by means of writing, photographing, drawing, mechanically or electronically reproducing or recording such secret scientific material," and whether he had intended to appropriate the use of that source code.  It answered both questions in the affirmative.

    The first issue the Court faced was what the term "tangible" meant in the context of the unlawful use statute.  The Court reviewed the background of the statute (which arose out of concerns that the conduct in a Federal case, United States v. Bottone, 365 F.2d 389 (2d Cir. 1966), might not be prohibited under New York law), but then noted that the term "tangible" is not defined in the Penal Law.  It noted that dictionaries could provide "useful guideposts" for determining the ordinary meaning of statutory terms; indeed, both the prosecution and Mr. Aleynikov had proposed definitions from Black's Law Dictionary for the interpretation of the word "tangible."  Mr. Aleynikov had suggested that it meant "capable of being touched," the State had argued that it meant "having or possessing physical form."

    The Court of Appeals rejected Mr. Aleynikov's proposed definition in two steps.  First, it asserted that, if construed that way, "the term does not apply to ink printed on paper any more readily than to source code, and provides no workable criterion."  Second, it indicated that the question was not whether source code was tangible (and, to conform with prior cases, the Court was constrained to agree that source code is intangible), but whether a copy of that source code would be tangible when downloaded.  Thus, the Court sought to distinguish between source code generally and a copy of source code taking up physical space on a hard drive or CD.

    The Court's position is curious, and appears to be based on a limited computer literacy.  The Court's first statement is odd, as there is no doubt that paper with printed indicia can be touched by hand.  On the other hand, virtual (that is, not printed) source code is not stored in the same format as it is printed; it is saved as binary code.  Therefore, it cannot be touched as compiled source code, even on a microscopic level.  There is a clear distinction that, while perhaps intellectually unsatisfying, is easy to police.  Second, even before it is saved, computer code takes up physical space (whether in memory or saved on media).  That is, the Court of Appeals makes a distinction where there is no difference.

    Notably, the Court struggles to provide any meaning to the term "tangible" in the phrase "tangible reproduction or representation."  It posits the example of memorization of source code, but notes that such memorization would not fall under the statute because the reproduction or representation must be "by means of writing, photographing, drawing, mechanically or electronically reproducing or recording."  It circumvents the conundrum by stating, "the word 'tangible,' as we interpret it, does not introduce redundancy; it adds a modest element to 'reproduction,' serving to emphasize that the crime consists in making a physical, not a mental, copy of secret scientific material."  But that "emphasis," in light of the requirement of certain means for making the reproduction, is redundancy.

    The Court then gets to the heart of its objection to Mr. Aleynikov's position, stating that "it would be absurd to suppose that the statute criminalizes photographs stored on film but not ones stored on a hard drive."  But that absurd result is for the legislature to prevent through an amendment of the statute, not the Court to fix through interpretation.[7]  The unlawful use statute was adopted in 1967, long before the internet was in common use.  The legislature had not yet criminalized computer crime specifically, and would not do so for almost two more decades.  And even now, there is a package of legislation proposed that would remedy the absurd juxtaposition noted by the Court.

    The Court of Appeals made short work of Mr. Aleynikov's second argument, that he did not intend to appropriate the relevant source code because he did not intend to deprive Goldman Sachs of the source code.  In doing so, it disaggregated the definition of "appropriate":  under the New York Penal Law, "[t]o 'appropriate' property of another to oneself or a third person means (a) to exercise control over it, or to aid a third person to  exercise control over it, permanently or for so extended a period or under such circumstances as to acquire the major portion of its economic value or benefit, or (b) to dispose of the property for the benefit of oneself or a third person."[8]  The Court asserted that the definition was intended to indicate that control could be exercised (i) permanently or (ii) for so extended a period or under such circumstances as to acquire the major portion of its economic value or benefit.  From that, it surmised that exercising permanent control over another's property would be sufficient, and asserted that Mr. Aleynikov intended to exercise control over the source code permanently, since he admittedly did not intend to return the copy of source code in his possession.

    The Court's resolution of the appropriation issue is ironic, as it elides the distinction between the source code and the copy of the source code it made in relation to "tangible reproduction or representation.  That is, Mr. Aleynikov certainly intended to keep the copy of source code he had made, but had no intent to control Goldman Sachs's use of its own copy of the source code.  But the Court did not address the inconsistency between the two interpretations.

    While the Court of Appeals was clearly bothered by the prospect of Mr. Aleynikov getting off on a "technicality," it substantially expanded the unlawful use statute to do so.  Of course, the language of a statute is not a technicality.  But the Court interpreting the statute extremely broadly is likely to chill behavior that the legislature did not intend to criminalize.  There is always tension between preventing harm to intellectual property owners and allowing employees freedom to move from job to job; the New York Court of Appeals drew the line far more to employers' liking because of the hard facts of the case.  In truth, that should have been the legislature's job.

    [1] For more details on Mr. Aleynikov’s conduct and prosecutions, please see the Patent Docs posts "Another Aleynikov Trade Secrets Case Ends with Narrower Statute" and "Aleynikov Conviction Reinstated by New York Appellate Court," as well as the Snippets article "New York v. Aleynikov: New York State's Penal Code (Like Federal Criminal Law) Does Not Cover Electronic Reproduction of Source Code."

    [2] The Economic Espionage Act is found at 18 U.S.C. § 1832 and the National Stolen Property Act is found at 18 U.S.C. § 2314.

    [3] United States v. Aleynikov, 676 F.3d 71, 76-79 (2d Cir. 2012).

    [4] See N.Y. Pen. L. § 165.07 ("A person is guilty of unlawful use of secret scientific material when, with intent to appropriate to himself or another the use of secret scientific material, and having no right to do so and no reasonable ground to believe that he has such right, he makes a tangible reproduction or representation of such secret scientific material by means of writing, photographing, drawing, mechanically or electronically reproducing or recording such secret scientific material.").

    [5] New York v. Aleynikov, 148 A.D. 3d 77 (N.Y. App. Div. [1st Dept.] 2017).

    [6] N.Y. Pen. L. § 155.00[4].

    [7] For example, after the Second Circuit reversed Mr. Aleynikov's conviction under the Economic Espionage Act, Congress moved quickly to amend the statute to cover future abuses of the same sort.  Pub. L. 112-236.

    [8] N.Y. Pen. L. 155.00[4].

  • CalendarMay 15, 2018 – "USPTO Post-Grant Patent Trials 2018: Change & Recalibration" (Practising Law Institute) – San Francisco

    May 17, 2018 – "Patenting Antibodies at the EPO" (J A Kemp) – 15:30 (Greenwich Mean Time)

    May 17, 2018 – "Patent Exclusivity Health Checks for Biologics: Are Your U.S. Patents Ready to Maximize ROI?" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 18, 2018 – "US-China: The Relationship and Concerns Raised in the Section 301 Investigation and Report" (Federal Circuit Bar Association) – 3:00 pm to 4:30 pm (EST)

    May 22, 2018 – "Sovereign Immunity and Patents at the PTAB and District Courts" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    May 22, 2018 – "Last Party Standing: Who Has Standing to Appeal Administrative Decisions to the Federal Circuit?" (Federal Circuit Bar Association) – 3:00 pm to 4:30 pm (EST)

    May 22, 2018 – "Nuances in Amending Patent Claims before the PTAB and Avoiding Tribal Immunity at the PTAB" (Intellectual Property Law Association of Chicago Litigation Committee) – 5:00 to 7:30 pm (CT), Chicago, IL

    May 24, 2018 – "Divided Infringement after Travel Sentry v. Tropp: Direct Infringement Liability for Third-Party Conduct" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 31, 2018 – "Oil States and SAS: Implications of the Supreme Court's Decisions for Patent Practice" (Strafford) – 1:00 to 2:30 pm (EDT)

    June 4-7, 2018 – BIO International Convention (Biotechnology Innovation Organization) – Boston, MA

    June 13-15, 2018 – Patent Fundamentals Bootcamp 2018: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – New York, NY

    June 25-27, 2018 – Summit on Biosimilars (American Conference Institute) – New York, NY

    July 18-20, 2018 – Patent Fundamentals Bootcamp 2018: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – San Francisco, CA

    September 21, 2018 – "USPTO Post-Grant Patent Trials 2018: Change & Recalibration" (Practising Law Institute) – New York & Groupcasts in Philadelphia, Indianapolis, New Brunswick, NJ, Pittsburgh, and Mechanicsburg, PA

  • BIO International Convention_shortThe Biotechnology Innovation Organization (BIO) will be holding its annual BIO International Convention June 4-7, 2018 in Boston, MA.  Founded in 1993, BIO is a nonprofit association seeking supportive biotechnology policies on behalf of biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.  The BIO International Convention serves to educate the public and policymakers about biotechnology, while fostering partnering meetings and other business development activities to keep the biotech industry growing.

    Descriptions of the Convention's 125+ Breakout Sessions and eight Super Sessions can be obtained here.  Among the sessions that may be of interest to Patent Docs readers are:

    Monday, June 4

    Intellectual Property Track Opening Plenary with Andrei Iancu, Under Secretary of Commerce for IP and Director, USPTO (Intellectual Property Track) — 1:00 to 2:15 pm (Room 259A, Level 2)

    Has Big Pharma Fixed its Broken Innovation Model? (Business Development & Finance Track) — 1:00 to 2:15 pm (Room 257AB, Level 2)

    Tuesday, June 5

    FDA Town Hall (Regulatory Innovation Track) — 11:00 am to 12:00 pm (Room 207, Level 2)

    Hatch-Waxman ANDA Cases and IPRs (Intellectual Property Track) — 3:00 to 4:00 pm (Room 208, Level 2)

    Global Leadership Forum: Is Biotechnology Innovation Globally Sustainable? (Emerging Opportunities in Global Markets Track) — 3:00 to 4:00 pm (Room 204AB, Level 2)

    IP Issues in Rare Diseases: Addressing the Unmet Need (Intellectual Property Track) — 4:15 to 5:15 pm (Room 208, Level 2)

    The Changing Face of Academic Technology Transfer (Translational Research Track) — 4:15 to 5:15 pm (Room 206AB, Level 2)

    Wednesday, June 6

    Functional Antibody Patents Are Dead: Long Live Functional Antibody Patents (Intellectual Property Track) — 11:00 am to 12:00 pm (Room 208, Level 2)

    Are Your Pharmaceutical Patents at Risk? (Intellectual Property Track) — 1:45 to 2:45 pm (Room 208, Level 2)

    Legal Certainty at an Affordable Price – the European Opposition Procedure (Intellectual Property Track) — 3:00 to 4:00 pm (Room 208, Level 2)

    Using America’s Seed Fund (SBIR/STTR) and NIH Technology Transfer to Accelerate Technology Development and Secure Follow-On Investments (Business Development & Finance Track) — 3:00 to 4:00 pm (Room 252AB, Level 2)

    State Universities, Indian Tribes, and Biotech Patent Law (Intellectual Property Track) — 4:15 to 5:15 pm (Room 208, Level 2) — panel includes Patent Docs author Kevin Noonan

    Thursday, June 7

    Fireside Chat with Dr. Scott Gottlieb, Commissioner, U.S. Food and Drug Administration — 9:00 to 9:45 am (Room 253ABC, Level 2)

    BIO - Good Times on Tap 2012As part of the Convention, more than 1,800 biotech companies, organizations, and institutions will participate in the BIO Exhibition.  A searchable list of exhibitors can be found here.  Information regarding registration and pricing can be obtained herePatent Docs authors Donald Zuhn, Kevin Noonan, and Andrew Williams will be attending BIO as part of the MBHB contingent.  Patent Docs readers who may be attending BIO are encouraged to stop by the MBHB booth (#2620).

    In addition, the Docs will be attending the MBHB reception at Black Rose Irish Pub (160 State Street, Boston) on Tuesday, June 5 from 8:00 pm to 1:00 am.  Additional information about the reception, including invitations for the event, can be picked up at the MBHB booth.